153710 — Optipharm Co Balance Sheet
0.000.00%
- KR₩77bn
- KR₩74bn
- KR₩20bn
- 34
- 12
- 29
- 11
Annual balance sheet for Optipharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Cash and Short Term Investments | 22,025 | 21,187 | 16,073 | 14,654 | 14,022 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1,290 | 1,338 | 2,292 | 1,880 | 1,580 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 25,676 | 25,867 | 21,548 | 20,476 | 18,675 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 13,347 | 13,613 | 17,717 | 18,325 | 23,789 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 41,321 | 41,168 | 41,182 | 39,275 | 43,319 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 5,524 | 7,851 | 9,264 | 11,601 | 12,734 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 7,541 | 10,213 | 12,171 | 14,131 | 15,983 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 33,780 | 30,955 | 29,011 | 25,144 | 27,335 |
Total Liabilities & Shareholders' Equity | 41,321 | 41,168 | 41,182 | 39,275 | 43,319 |
Total Common Shares Outstanding |